{"a":[{"_":"Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent","$":{"href":"/pharma/amgen-az-tezspire-phase-3-eosinophilic-esophagitis-turning-heat-dupixent","hreflang":"en"}}]}
Phase 3positiveTezspireDupixentPositive
AI Analysis
Summary
Amgen and AstraZeneca's Tezspire achieved a phase 3 win in eosinophilic esophagitis, positioning the drug as a competitive challenge to Sanofi and Regeneron's Dupixent in the inflammatory disease market.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 win in eosinophilic esophagitis
Importance:8/10
Sentiment:
0.80
Phase 3eosinophilic esophagitisinflammatory diseaseDupixent competition
Read the original article
Published by FiercePharma on August 27, 2026 9:51 AM